WuXi PharmaTech Expands J&J Research Deal, Posts Higher Profits
This article was originally published in The Pink Sheet Daily
Executive Summary
However, firm sees sharper risks sparked by global financial crisis.
You may also be interested in...
Charles River Set To Launch First Global CRO Preclinical Testing Center In China
BEIJING - Charles River Laboratories, one of the world's leading contract research organizations, is set to open a new preclinical testing facility this week in the rapidly expanding Chinese market, according to Senior VP Christopher Perkins
WuXi PharmaTech Set For Sales Synergy with U.S. Subsidiary AppTec
BEIJING - WuXi PharmaTech, one of China's fastest-growing contract research organizations in the pharmaceutical and medical device sectors, is laying the groundwork to boost earnings through cross-selling synergies with its recently acquired U.S.-based biologics firm AppTec Laboratory Services
Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population
Bayer's antidiabetes drug Glucobay (acarbose), an alpha-glucosidase inhibitor, is already one of the company's strongest products in China.